| 群体药代动力学用于西罗莫司个体化给药研究进展 |
| |
| 引用本文： | 薛领,缪丽燕. 群体药代动力学用于西罗莫司个体化给药研究进展[J]. 中国临床药理学杂志, 2010, 26(1) |
| |
| 作者姓名： | 薛领 缪丽燕 |
| |
| 作者单位： | 苏州大学附属第一医院,临床药理研究室,江苏苏州,215006 |
| |
| 摘 要： | 西罗莫司(免疫抑制剂)是一种新型免疫抑制剂,在临床上用于预防实体器官移植后的排斥反应。本文将影响其吸收、分布、消除的各种因素,如人口学特征、合并用药、血液生化指标、CYP3A5基因多态性、肝肾功能等,对西罗莫司群体药代动力学(PPK)参数的影响进行了综述。
|
| 关 键 词： | 西罗莫司 个体化给药 群体药代动力学 免疫抑制剂 基因多态性 |
Development of population pharmacokinetics in clinical individual dosage of sirolimus |
| |
| XUE Ling,MIAO Li-yan. Development of population pharmacokinetics in clinical individual dosage of sirolimus[J]. The Chinese Journal of Clinical Pharmacology, 2010, 26(1) |
| |
| Authors: | XUE Ling MIAO Li-yan |
| |
| Affiliation: | Department of Clinical Pharmacology;The First Affiliated Hospital of Soochow University;Shuzhou 215006;Jiangsu Province;China |
| |
| Abstract: | Sirolimus that is a new immunosuppressive agent has been approved for preventing rejection after solid organs transplantation in clinical the setting.The article reviews some variability,e.g.demographic characteristics,incorporated drug,blood and biochemical indicator,the polymorphism of CYP3A5,hepat-and kidney function and other factors,that influence the parameters of sirolimus population pharmacokinetics(PPK) through refering a great quantity internal and overseas literatures. |
| |
| Keywords: | sirolimus individual dosage population pharmacokinetics immunosuppressive agent polymorphism |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
